The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2025

Filed:

May. 10, 2022
Applicant:

The Regents of the University of Colorado, Denver, CO (US);

Inventors:

Brian Freed, Centennial, CO (US);

Christina Roark, Englewood, CO (US);

Elizabeth Sunderhaus, W. Henrietta, NY (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/74 (2006.01); A61K 35/17 (2015.01); A61K 35/28 (2015.01); A61K 39/00 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); C12N 5/0775 (2010.01); C12N 15/62 (2006.01); C12N 15/86 (2006.01); C12Q 1/6881 (2018.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70539 (2013.01); A61K 35/28 (2013.01); A61K 39/461 (2023.05); A61K 39/4621 (2023.05); A61K 39/46433 (2023.05); A61P 37/02 (2018.01); A61P 37/06 (2018.01); C12N 5/0663 (2013.01); C12N 15/625 (2013.01); C12N 15/86 (2013.01); C12Q 1/6881 (2013.01); A61K 38/00 (2013.01); C12N 2740/10043 (2013.01);
Abstract

Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and/or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.


Find Patent Forward Citations

Loading…